CN108350086A - 基于天然抗体的靶向构建体及其用途 - Google Patents

基于天然抗体的靶向构建体及其用途 Download PDF

Info

Publication number
CN108350086A
CN108350086A CN201480017698.6A CN201480017698A CN108350086A CN 108350086 A CN108350086 A CN 108350086A CN 201480017698 A CN201480017698 A CN 201480017698A CN 108350086 A CN108350086 A CN 108350086A
Authority
CN
China
Prior art keywords
antibody
fragment
construct
seq
annexin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201480017698.6A
Other languages
English (en)
Chinese (zh)
Inventor
B·M·罗勒
M·霍乐尔斯
S·汤姆林森
J·M·瑟曼
C·阿特金森
L·库里克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Colorado Council Co, University of
MUSC Foundation for Research and Development
US Department of Veterans Affairs
Original Assignee
Colorado Council Co, University of
MUSC Foundation for Research and Development
US Department of Veterans Affairs
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Colorado Council Co, University of, MUSC Foundation for Research and Development, US Department of Veterans Affairs filed Critical Colorado Council Co, University of
Publication of CN108350086A publication Critical patent/CN108350086A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201480017698.6A 2013-01-23 2014-01-23 基于天然抗体的靶向构建体及其用途 Pending CN108350086A (zh)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201361755968P 2013-01-23 2013-01-23
US201361755960P 2013-01-23 2013-01-23
US61/755,960 2013-01-23
US61/755,968 2013-01-23
US201361771565P 2013-03-01 2013-03-01
US201361771560P 2013-03-01 2013-03-01
US61/771,565 2013-03-01
US61/771,560 2013-03-01
PCT/US2014/012831 WO2014116880A1 (en) 2013-01-23 2014-01-23 Targeting constructs based on natural antibodies and uses thereof

Publications (1)

Publication Number Publication Date
CN108350086A true CN108350086A (zh) 2018-07-31

Family

ID=51228044

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480017698.6A Pending CN108350086A (zh) 2013-01-23 2014-01-23 基于天然抗体的靶向构建体及其用途

Country Status (9)

Country Link
US (2) US20160083469A1 (https=)
EP (1) EP2948480A4 (https=)
JP (1) JP6563815B2 (https=)
CN (1) CN108350086A (https=)
AU (3) AU2014209350B8 (https=)
CA (1) CA2899034A1 (https=)
HK (1) HK1218300A1 (https=)
IL (2) IL240084B (https=)
WO (1) WO2014116880A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113660944A (zh) * 2018-12-11 2021-11-16 Q32生物公司 用于补体相关疾病的融合蛋白构建体

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20200182T1 (hr) 2014-02-25 2020-05-01 Achillion Pharmaceuticals, Inc. Aril, heteroaril i heterociklični spojevi za liječenje komplementom posredovanih poremećaja
CN106687123A (zh) * 2014-06-05 2017-05-17 科罗拉多州大学评议会 Map44多肽和基于天然抗体的构建体及其用途
EP3892291A1 (en) * 2014-08-28 2021-10-13 Tufts University Compositions, methods and kits for treating complement related disorders
WO2017035351A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amino compounds for treatment of medical disorders
WO2017035401A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amide compounds for treatment of immune and inflammatory disorders
WO2017035355A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Ether compounds for treatment of medical disorders
AR105809A1 (es) 2015-08-26 2017-11-08 Achillion Pharmaceuticals Inc Compuestos para el tratamiento de trastornos médicos
WO2017035362A1 (en) * 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Use of complement pathway inhibitor compounds to mitigate adoptive t-cell therapy associated adverse immune responses
AR106018A1 (es) 2015-08-26 2017-12-06 Achillion Pharmaceuticals Inc Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos
WO2017035357A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Phosphonate compounds for treatment of medical disorders
WO2017035409A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders
AR105808A1 (es) 2015-08-26 2017-11-08 Achillion Pharmaceuticals Inc Compuestos de amida para el tratamiento de trastornos médicos
WO2017035408A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Compounds for treatment of immune and inflammatory disorders
WO2017035361A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Disubstituted compounds for the treatment of medical disorders
WO2017035405A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amino compounds for treatment of immune and inflammatory disorders
GB201519086D0 (en) * 2015-10-28 2015-12-09 Syncona Partners Llp Gene Therapy
EP3526249A4 (en) * 2016-10-17 2020-07-01 Musc Foundation for Research Development COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING INJURY ASSOCIATED WITH A GRAFT
WO2018075474A1 (en) * 2016-10-17 2018-04-26 Medical University Of South Carolina Compositions and methods for treating central nervous system injury
EP3589287B1 (en) 2017-03-01 2022-09-14 Achillion Pharmaceuticals, Inc. Macrocyclic compounds for treatment of medical disorders
CN110603252A (zh) 2017-03-01 2019-12-20 艾其林医药公司 用于治疗医学障碍的芳基、杂芳基和杂环药物化合物
WO2018160891A1 (en) 2017-03-01 2018-09-07 Achillion Pharmaceutical, Inc. Pharmaceutical compounds for treatment of medical disorders
US20190038623A1 (en) 2017-08-02 2019-02-07 Achillion Pharmaceuticals, Inc. Therapeutic regimens for treatment of paroxysmal nocturnal hemoglobinuria
TWI818919B (zh) * 2017-08-15 2023-10-21 美商歐米諾斯公司 用於治療和／ 或預防與造血幹細胞移植有關的移植物抗宿主病和／ 或瀰漫性肺泡出血和／ 或靜脈閉塞性病的方法
GB201800620D0 (en) 2018-01-15 2018-02-28 Univ Manchester C3b Binding Polypeptide
WO2020051532A2 (en) 2018-09-06 2020-03-12 Achillion Pharmaceuticals, Inc. Macrocyclic compounds for the treatment of medical disorders
US11814363B2 (en) 2018-09-06 2023-11-14 Achillion Pharmaceuticals, Inc. Morphic forms of danicopan
EP3852874A1 (en) * 2018-09-17 2021-07-28 Kyoto University Administration of an anti-c5 agent for treatment of hepatic injury or failure
BR112021005506A2 (pt) 2018-09-25 2021-06-15 Achillion Pharmaceuticals, Inc. formas mórficas de inibidores de fator complementar d
GB2583560A (en) 2018-12-11 2020-11-04 Admirx Inc Fusion protein constructs for complement associated disease
KR20210104071A (ko) 2018-12-17 2021-08-24 아칠리온 파르마세우티칼스 인코포레이티드 보체 매개 장애의 치료를 위한 표적 투약
WO2020198062A1 (en) 2019-03-22 2020-10-01 Achillion Pharmaceuticals, Inc. Pharmaceutical compounds for the treatment of complement mediated disorders
WO2021247487A1 (en) * 2020-06-01 2021-12-09 Medical University Of South Carolina Recombinant fusion proteins targeting p-selectin, and methods of use thereof for treating diseases and disorders
GB2628281A (en) * 2022-01-07 2024-09-18 Jumio Corp Biometric authentication using head-mounted devices
CN115963841A (zh) * 2023-01-16 2023-04-14 大连海事大学 基于改进lvs制导的无人帆船动态事件触发控制方法
WO2024194686A2 (en) 2023-03-17 2024-09-26 Oxitope Pharma B.V. Anti-phosphocholine antibodies and methods of use thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005120519A1 (en) * 2004-06-10 2005-12-22 The Walter And Eliza Hall Institute Of Medical Research Glycosylphosphatidylinositol glycan signalling via integrins functioning as glycan specific receptors
WO2007112403A2 (en) * 2006-03-27 2007-10-04 The Regents Of The University Of Colorado Prevention and treatment of ischemia-reperfusion injury
CN101809034A (zh) * 2007-06-07 2010-08-18 健泰科生物技术公司 C3b抗体及用于预防和治疗补体相关病症的方法
WO2011057158A1 (en) * 2009-11-05 2011-05-12 Taligen Therapeutics, Inc. Treatment of paroxysmal nocturnal hemoglobinuria, hemolytic anemias and disease states involving intravascular and extravascular hemolysis

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101235089A (zh) * 2008-03-04 2008-08-06 张秀茹 抗β2GPI基因工程Fab抗体
US9815890B2 (en) * 2010-06-22 2017-11-14 The Regents Of The University Of Colorado, A Body Corporate Antibodies to the C3d fragment of complement component 3

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005120519A1 (en) * 2004-06-10 2005-12-22 The Walter And Eliza Hall Institute Of Medical Research Glycosylphosphatidylinositol glycan signalling via integrins functioning as glycan specific receptors
WO2007112403A2 (en) * 2006-03-27 2007-10-04 The Regents Of The University Of Colorado Prevention and treatment of ischemia-reperfusion injury
CN101809034A (zh) * 2007-06-07 2010-08-18 健泰科生物技术公司 C3b抗体及用于预防和治疗补体相关病症的方法
WO2011057158A1 (en) * 2009-11-05 2011-05-12 Taligen Therapeutics, Inc. Treatment of paroxysmal nocturnal hemoglobinuria, hemolytic anemias and disease states involving intravascular and extravascular hemolysis

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ABYSIS-EMBL-IG DQ220793: "abYsis-EMBL-IG DQ220793", 《ABYSIS ACCESSION：ABB76651.1 》 *
ABYSIS-EMBL-IG GQ353307: "abYsis-EMBL-IG GQ353307", 《ABYSIS ACCESSION：ACV40677.1》 *
ABYSIS-EMBL-IG J04438: "abYsis-EMBL-IG J04438", 《ABYSIS ACCESSION：AAA39009.1》 *
ANDREW ELVINGTON等: "Pathogenic Natural Antibodies Propagate Cerebral Injury Following Ischemic Stroke in Mice", 《THE JOURNAL OF IMMUNOLOGY》 *
LIUDMILA KULIK等: "Pathogenic Natural Antibodies Recognizing Annexin IV Are Required to Develop Intestinal Ischemia-Reperfusion Injury", 《THE JOURNAL OF IMMUNOLOGY》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113660944A (zh) * 2018-12-11 2021-11-16 Q32生物公司 用于补体相关疾病的融合蛋白构建体

Also Published As

Publication number Publication date
EP2948480A4 (en) 2016-12-07
JP6563815B2 (ja) 2019-08-21
IL281498A (en) 2021-04-29
US20160083469A1 (en) 2016-03-24
WO2014116880A1 (en) 2014-07-31
EP2948480A1 (en) 2015-12-02
AU2019201826B2 (en) 2021-06-17
AU2014209350B2 (en) 2019-04-04
JP2016513080A (ja) 2016-05-12
HK1218300A1 (zh) 2017-02-10
AU2014209350A1 (en) 2015-08-06
US20210388080A1 (en) 2021-12-16
IL240084A0 (en) 2015-09-24
AU2019201826A1 (en) 2019-04-18
IL240084B (en) 2021-04-29
CA2899034A1 (en) 2014-07-31
AU2021232692A1 (en) 2021-10-07
AU2014209350B8 (en) 2019-04-18

Similar Documents

Publication Publication Date Title
AU2019201826B2 (en) Targeting constructs based on natural antibodies and uses thereof
US20250000955A1 (en) Map44 polypeptides and constructs based on natural antibodies and uses thereof
US9815890B2 (en) Antibodies to the C3d fragment of complement component 3
NZ719476A (en) Methods for treating conditions associated with masp-2 dependent complement activation
US11806389B2 (en) Compositions and methods for treating central nervous system injury
JP2018530574A (ja) 患者の加齢黄斑変性を治療する方法
US20240018247A1 (en) Recombinant Fusion Proteins Targeting P-selectin, and Methods of Use Thereof for Treating Diseases and Disorders
AU2018200437A1 (en) Methods for treating conditions associated with MASP-2 dependent complement activation
TW202348800A (zh) 用補體旁路途徑抑制劑治療鐮狀細胞病或β地中海貧血之方法
HK40114300A (zh) 用於治疗和/或预防弥漫性肺泡出血的方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20180731